Humacyte stock soars after Symvess gains DOD electronic catalog listing
Investing.com -- Humacyte Inc (NASDAQ:HUMA) stock surged 21% after the company announced that its Symvess product received Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency.
The ECAT approval makes Symvess available to healthcare professionals treating military service members, veterans, and patients receiving care at Department of Defense (DOD) and U.S. Department of Veterans Affairs facilities. This listing provides these federal agencies with direct access to the company’s bioengineered human tissue product.
Symvess, described as an acellular tissue engineered vessel, received FDA approval for extremity vascular trauma indication in December 2024. The product is part of Humacyte’s commercial-stage biotechnology platform that develops universally implantable, bioengineered human tissue.
"We are pleased that Symvess is now listed in the ECAT system, making the product more readily available to healthcare professionals treating military personnel and their families," said Dr. Laura Niklason, President and CEO of Humacyte. "We have received positive feedback in our interactions with a number of DOD hospitals, and we look forward to making Symvess available to more patients in need."
The company noted that for uses beyond the FDA-approved extremity vascular trauma indication, the acellular tissue engineered vessel remains an investigational product that has not received regulatory approval.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is HUMA one of them?
